Boehringer Ingelheim struck a multi-program, preclinical options deal with Beijing-headquartered Sino Biopharmaceutical for six assets spanning antibody-drug conjugates and T-cell engagers. Under the agreement, Boehringer will pay $358 million up front for options on the programs, with total milestones reported at $7 billion. The partnership again reflects the continued draw of China-originated modalities for Western pharma as companies seek pipeline breadth in differentiated therapeutic platforms. The deal also signals that ADC and engager strategies remain central to external sourcing as companies compete to secure earlier-stage innovation. For investors, the magnitude of upfront payments and milestone totals underscores how seriously counterparties are valuing preclinical platform work, even in a period of heightened scrutiny of deal risk and regulatory timelines.